<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000488414">
  <TermName>RFT5-dgA immunotoxin</TermName>
  <TermPronunciation>(... IH-myoo-noh-TOK-sin)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A monoclonal antibody linked to a toxic substance. It is being studied in the treatment of melanoma that has spread to distant parts of the body. RFT5-dgA immunotoxin is made in the laboratory. It can find and kill certain white blood cells that prevent the immune system from killing cancer cells. Also called IgG-RFT5-dgA.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000718411" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;RFT5-dgA immunotoxin&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000718410" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;inmunotoxina RFT5-dgA&quot;" language="es" id="_4"/>
  <SpanishTermName>inmunotoxina RFT5-dgA</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Anticuerpo monoclonal ligado a una sustancia tóxica. Está en estudio para el tratamiento del melanoma que se ha diseminado hasta partes distantes del cuerpo. La inmunotoxina RFT5-dgA se produce en el laboratorio. Puede encontrar y destruir ciertos glóbulos blancos que impiden que el sistema inmunitario destruya las células cancerosas. También se llama IgG-RFT5-dgA.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2006-12-01</DateFirstPublished>
  <DateLastModified>2008-11-21</DateLastModified>
</GlossaryTerm>
